의약품이상사례보고시스템 데이터베이스를 활용한 비스테로이드성 소염진통제 계열 간 약물이상반응 비교 분석
Disproportionality Analysis of Adverse Drug Reactions across NSAID Classes Using the KAERS Database
Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used to manage pain and inflammation but are associated with adverse events (AEs) across various organ systems. However, organ-specific AE profiles among different NSAID classes remain underexplored. This study aimed to compare AE patterns across NSAID classes using national pharmacovigilance data. Methods: A total of 54,251 NSAID-related AE reports from 2017 to 2021 were extracted from the Korea Adverse Event Reporting System (KAERS). NSAIDs were classified into six groups: propionic acids, acetic acids, oxicams, fenamic acids, COX-2 inhibitors, and salicylic acids. AEs were categorized into nine System Organ Classes (SOCs) based on Medical Dictionary for Regulatory Activities (MedDRA) terminology. Disproportionality analysis was performed using Reporting Odds Ratio (ROR) and Proportional Reporting Ratio (PRR) to identify class-specific AE signals. Results: The most frequently reported SOCs were skin disorders (30.1%) and gastrointestinal events (24.0%). Salicylic acids showed the highest disproportionality for musculoskeletal and connective tissue disorders [ROR (95% CI)=4.18 (3.56-4.90); PRR (95% CI)=4.11 (3.51-4.81)]. Fenamic acids were notably associated with skin-related AEs [ROR (95% CI)=1.86 (1.69-2.04); PRR (95% CI)=1.47 (1.40-1.55)], while COX-2 inhibitors were linked to endocrine [ROR (95% CI)=1.91 (1.47-2.47); PRR (95% CI=1.90 (1.47-2.46)] and genitourinary disorders [ROR (95% CI)=1.92 (1.59-2.31); PRR (95% CI)=1.90 (1.58-2.28)]. Conclusion: NSAID classes demonstrate distinct AE disproportionality patterns, suggesting class-specific organ susceptibilities. These findings emphasize the need for personalized NSAID selection and further research into predictive safety models.
목차
ABSTRACT 방법 연구설계 데이터 전처리 보고분율비와 보고오즈비 산출 결과 NSAIDs 이상사례 분포 NSAIDs 이상사례 보고불균형 고찰 결론 이해 상충 References
키워드
Adverse drug reaction reporting systemsnon-steroidal anti-inflammatory drugs (NSAIDs)pharmacovigilanc